M
Murali Chintagumpala
Researcher at Boston Children's Hospital
Publications - 68
Citations - 3958
Murali Chintagumpala is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Medulloblastoma & Carboplatin. The author has an hindex of 26, co-authored 68 publications receiving 3531 citations. Previous affiliations of Murali Chintagumpala include Duke University & Royal Children's Hospital.
Papers
More filters
Journal ArticleDOI
Genomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic Alterations
Margaret C. Thompson,Christine E. Fuller,Twala L. Hogg,James T. Dalton,David Finkelstein,Ching C. Lau,Murali Chintagumpala,Adekunle M. Adesina,David M. Ashley,Stewart J. Kellie,Michael D. Taylor,Tom Curran,Amar Gajjar,Richard J. Gilbertson +13 more
TL;DR: Genome-wide expression profiles can partition large tumor cohorts into subgroups that are enriched for specific genetic alterations that may assist ultimately in the selection of patients for future clinical trials of molecular targeted therapies.
Journal ArticleDOI
Neurocognitive Consequences of Risk-Adapted Therapy for Childhood Medulloblastoma
Raymond K. Mulhern,Shawna L. Palmer,Thomas E. Merchant,Dana Wallace,Mehmet Kocak,Pim Brouwers,Kevin R. Krull,Murali Chintagumpala,Robyn Stargatt,David M. Ashley,Vida L. Tyc,Larry E. Kun,James M. Boyett,Amar J. Gajjar +13 more
TL;DR: Young age at diagnosis was the most prominent risk factor for neurocognitive deficits among survivors of MB despite reductions in CSI dosing and efforts to limit the boost volume.
Journal ArticleDOI
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032
Giles W. Robinson,Brent A. Orr,Gang Wu,Sridharan Gururangan,Tong Lin,Ibrahim Qaddoumi,Roger J. Packer,Stewart Goldman,Michael D. Prados,Annick Desjardins,Murali Chintagumpala,Naoko Takebe,Sue C. Kaste,Michael Rusch,Sariah Allen,Arzu Onar-Thomas,Clinton F. Stewart,Maryam Fouladi,James M. Boyett,Richard J. Gilbertson,Tom Curran,David W. Ellison,Amar Gajjar +22 more
TL;DR: Molecular analyses support the hypothesis that SMO inhibitor activity depends on the genomic aberrations within the tumor and should be advanced in SHH-MB studies.
Journal ArticleDOI
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort
Sebastian M. Waszak,Paul A. Northcott,Paul A. Northcott,Ivo Buchhalter,Giles W. Robinson,Christian Sutter,Susanne N. Groebner,Kerstin Grund,Laurence Brugières,David T.W. Jones,Kristian W. Pajtler,Kristian W. Pajtler,A. Sorana Morrissy,Marcel Kool,Dominik Sturm,Dominik Sturm,Lukas Chavez,Aurélie Ernst,Sebastian Brabetz,Sebastian Brabetz,Michael Hain,Thomas Zichner,Maia Segura-Wang,Joachim Weischenfeldt,Tobias Rausch,Balca R. Mardin,Xin Zhou,Cristina Baciu,Christian Lawerenz,Jennifer A. Chan,Pascale Varlet,Léa Guerrini-Rousseau,Daniel W. Fults,Wiesława Grajkowska,Peter Hauser,Nada Jabado,Young Shin Ra,Karel Zitterbart,Suyash Shringarpure,Francisco M. De La Vega,Carlos Bustamante,Ho Keung Ng,Arie Perry,Tobey J. MacDonald,Pablo Hernáiz Driever,Anne Bendel,Daniel C. Bowers,Geoffrey McCowage,Murali Chintagumpala,Richard J. Cohn,Tim Hassall,Gudrun Fleischhack,Tone Eggen,Finn Wesenberg,Finn Wesenberg,Maria Feychting,Birgitta Lannering,Joachim Schüz,Christoffer Johansen,Tina Veje Andersen,Martin Röösli,Claudia E. Kuehni,Michael A. Grotzer,Kristina Kjaerheim,Camelia M. Monoranu,Tenley C. Archer,Tenley C. Archer,Elizabeth S. Duke,Scott L. Pomeroy,Scott L. Pomeroy,Redmond Shelagh,Stephan Frank,David Sumerauer,Wolfram Scheurlen,Marina Ryzhova,Till Milde,Till Milde,Christian P. Kratz,David Samuel,Jinghui Zhang,David A. Solomon,Marco A. Marra,Roland Eils,Claus R. Bartram,Katja von Hoff,Katja von Hoff,Stefan Rutkowski,Vijay Ramaswamy,Richard J. Gilbertson,Andrey Korshunov,Andrey Korshunov,Michael D. Taylor,Peter Lichter,David Malkin,Amar Gajjar,Jan O. Korbel,Stefan M. Pfister,Stefan M. Pfister +97 more
TL;DR: The prevalence of genetic predispositions differed between molecular subgroups in the retrospective cohort and was highest for patients in the MBSHH subgroup, and survival estimates differed significantly across patients with germline mutations in different medulloblastoma predisposition genes.
Journal ArticleDOI
Retinoblastoma: Review of Current Management
Murali Chintagumpala,Patricia Chévez-Barrios,Evelyn A. Paysse,Sharon E. Plon,Richard L. Hurwitz +4 more
TL;DR: The most common ocular cancer in children is retinoblastoma, and exciting discoveries using animal models are providing new insights into the development of this disease and opening new avenues for targeted therapies that may lead to high cure rates with minimal toxicities.